#Vosevi

A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco

In a recent trial, Gilead’s regimen was highly successful in a group that included those with and without HIV coinfection.

In a recent study of people whose previous hep C regimen failed to cure their infection, Vosevi cured almost all of them.

Ninety-seven percent of those who took the Gilead regimen after failing a previous therapy were cured in a recent study.

With many hepatitis C treatments on the market today, patients may ask which hepatitis C treatment is right for me? What’s the difference?

Among a large group treated with minimal or no liver fibrosis, liver-health problems were almost nonexistent up to three years later.

The U.S. FDA released November 13, 2017 new updates on Hepatitis C treatment medications.

A roundup of key findings from the Annual Meeting of the American Association for the Study of Liver Diseases in Washington, DC

Having hepatitis C with evidence of resistance to medications did not impact the chances of a cure in a recent study.

Among a large group treated with minimal or no liver fibrosis, liver-health problems were almost nonexistent up to three years later.

One research team has broken down the risk and benefits associated with treating more people in eight weeks or fewer.

Those with stage 3 CKD saw their kidney function improve after treatment with various combo regimens, including Harvoni.

It approved 12 weeks of Gilead Sciences’ Vosevi for the re-treatment of adults with all genotypes of HCV who do not have cirrhorsis.

A promising new regimen that will address unmet needs for this population is poised for FDA approval.

A look at Vosevi, the newest treatment for chronic hepatitis C virus infection for people without cirrhosis or with compensated cirrhosis